Ordinary Index Rebalancing in the Solactive Pharma & Biotech Opportunity Index | November 2019

In the ordinary rebalance the following composition will be implemented:

3SBIO INC
ALKERMES PLC
ARENA PHARMACEUTICALS INC
BIOMARIN PHARMACEUTICAL INC
BLUEBIRD BIO INC
CAMBREX CORP
CHINA BIOLOGIC PRODUCTS HOLD
CHINA MEDICAL SYSTEM HOLDINGS LTD
CHINA TRADITIONAL CHINESE MEDICINE HOLDINGS CO LTD
EMERGENT BIOSOLUTIONS INC
EXELIXIS INC
HIKMA PHARMACEUTICALS PLC
HORIZON THERAPEUTICS PLC
HYPERA SA
IPSEN SA
JAZZ PHARMACEUTICALS PLC
LUYE PHARMA GROUP LTD
MERCK KGAA
MYLAN NV
NEKTAR THERAPEUTICS
ONO PHARMACEUTICAL CO LTD ORD
PTC THERAPEUTICS INC
RICHTER GEDEON VEGYESZETI GYAR NYILVANOSAN MUKODO RT.
SANTEN PHARMACEUTICAL CO LTD ORD
SAWAI PHARMACEUTICAL CO LTD ORD
SHIONOGI & CO LTD ORD
SUMITOMO DAINIPPON PHARMA CO ORD
SWEDISH ORPHAN BIOVITRUM AB
UCB SA
YUHAN CORP ORD